Description: The new product should help protect against shortages and offer a lower-cost option, the FDA said
Date: Aug 16, 2018
Questions for discussion:
- Explain the rise in stock price of Teva and fall of Mylan, given no pricing or sales estimates have been released yet for the new product?
- Do you think competition will actually lower the generic price of the product or will Tevla likely match the current generic price offer to consumers?
- What would you advise management at both firms?